Because of its excellent safety profile and broad spectrum of activity, ivermectin is catalogued by the World Health Organisation as an essential medicine and is regarded by many as a "magic bullet" for global health.
The Japanese Journal of Antibiotics: Global trends in clinical studies of ivermectin (authored by 4 doctors, including Satoshi Ōmura, winner of the Nobel Prize in 2015 for his work on ivermectin)
As of the 27th of February 2021, the results of 42 clinical studies worldwide have undergone meta-analysis and concluded that ivermectin is effective in the treatment and prevention of COVID-19. In the UK, a consensus-based recommendation by 75 healthcare professionals from 17 countries around the world has been carried out and submitted to the WHO to further encourage the issuance of guidelines for the use of ivermectin in the treatment and prevention of COVID-19.
The Journal of Antibiotics: Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations
Antiviral (e.g. HIV, dengue, encephalitis)
Recent research has confounded the belief, held for most of the past 40 years, that ivermectin was devoid of any antiviral characteristics. Ivermectin has been found to potently inhibit replication of the yellow fever virus, with EC50 values in the sub-nanomolar range. It also inhibits replication in several other flaviviruses, including dengue, Japanese encephalitis and tick-borne encephalitis, probably by targeting non-structural 3 helicase activity. Ivermectin inhibits dengue viruses and interrupts virus replication, bestowing protection against infection with all distinct virus serotypes, and has unexplored potential as a dengue antiviral.
Ivermectin has also been demonstrated to be a potent broad-spectrum specific inhibitor of importin α/β-mediated nuclear transport and demonstrates antiviral activity against several RNA viruses by blocking the nuclear trafficking of viral proteins. It has been shown to have potent antiviral action against HIV-1 and dengue viruses, both of which are dependent on the importin protein superfamily for several key cellular processes. Ivermectin may be of import in disrupting HIV-1 integrase in HIV-1 as well as NS-5 (non-structural protein 5) polymerase in dengue viruses.
Monash Biomedicine Discovery Institute: Lab experiments show anti-parasitic drug, Ivermectin, eliminates SARS-CoV-2 in cells in 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint venture of the University of Melbourne and Royal Melbourne Hospital, has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.
The Monash Biomedicine Discovery Institute’s Dr Kylie Wagstaff, who led the study, said the scientists showed that the drug, Ivermectin, stopped the SARS-CoV-2 virus growing in cell culture within 48 hours.
“We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” Dr Wagstaff said.
Ivermectin is an FDA-approved anti-parasitic drug that has also been shown to be effective in vitro against a broad range of viruses including HIV, Dengue, Influenza and Zika virus.
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
[A] significant difference was found in patients with higher median plasma IVM levels (72% IQR 59–77) versus untreated controls (42% IQR 31–73) (p = 0·004).
U.S. Pharmacist: Common Supplements Might Reduce COVID Severity
For prophylaxis, the medical school recommends vitamin C (500 mg) and quercetin (250 mg-500 mg twice a day) with zinc (75 mg-100 mg per day), melatonin (0.3 mg-2 mg) each night, and vitamin D3 (1,000-4,000 IU per day). Famotidine (20 mg-40 mg per day) may be added to the mix. For patients with mild symptoms, EVMS recommends the same combination, with optional additions of ivermectin (150 ug-200 ug per kg as a single dose), and one low-dose or regular aspirin per day.
The Journal of Antibiotics: The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article
Although several drugs received Emergency Use Authorization for COVID-19 treatment with unsatisfactory supportive data, Ivermectin, on the other hand, has been sidelined irrespective of sufficient convincing data supporting its use.
Los Angeles Times: The FDA didn’t ‘approve’ Pfizer’s COVID-19 vaccine. Here’s why (Dec 2020)
Another important condition for issuing an EUA is that “there are no adequate, approved, and available alternatives” to the product being authorized.
Matt Taibbi: Why Has "Ivermectin" Become a Dirty Word?
At the worst moment, Internet censorship has driven scientific debate itself underground.
If the FDA were driven by science and evidence, it would give an emergency-use authorization for ivermectin for Covid-19. Instead, the FDA asserts without evidence that ivermectin is dangerous.
Mainichi: ノーベル賞学者・大村智博士が「予防はワクチン 治療はイベルメクチン」
Dr. Satoshi Omura, Nobel Prize scholar: "Vaccines for prevention, ivermectin for treatment"
Nikkei: 東京都医師会、イベルメクチン投与を提言 重症化予防で
"Tokyo Metropolitan Medical Association recommends ivermectin administration to prevent serious illness" 📺
New Microbes and New Infections: Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments.
[T]he drug is considered safe enough to give to almost everyone except the youngest infants and pregnant women.
Interviews with doctors, nurses, and others whose lives were saved by ivermectin:
Many more interviews here
/misc | Aug 28, 2021
Subscribe or visit the archives.